Compare BWB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWB | ALT |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.1M | 573.8M |
| IPO Year | 2018 | 2005 |
| Metric | BWB | ALT |
|---|---|---|
| Price | $20.83 | $3.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $21.67 | $17.67 |
| AVG Volume (30 Days) | 84.7K | ★ 3.1M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.66 | 25.37 |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $24.57 | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | $20.31 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $16.06 | $2.56 |
| 52 Week High | $22.62 | $6.44 |
| Indicator | BWB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 55.74 |
| Support Level | $20.81 | $3.18 |
| Resistance Level | $22.01 | $3.32 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 28.96 | 36.67 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.